Nrc Health (NRC) EBITDA Margin (2010 - 2026)

Nrc Health has disclosed EBITDA Margin across 17 years of filings, most recently posting 16.0% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 16.0%, down 962.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.52% (down 422.0% YoY), and the FY2025 annual result was 2.73%, down 207.0% from the prior year.
• EBITDA Margin came in at 16.0% for Q1 2026 at Nrc Health, up from 40.27% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 30.83% in Q2 2022 to a low of 66.35% in Q4 2022.
• The 5-year median for EBITDA Margin is 24.81% (2024), against an average of 10.71%.
• Across the five-year window, EBITDA Margin slumped 9997 bps in 2022 and soared 9717 bps in 2023, its largest moves.
• Nrc Health's EBITDA Margin stood at 66.35% in 2022, then jumped by 146 bps to 30.81% in 2023, then tumbled by 265 bps to 50.78% in 2024, then climbed by 21 bps to 40.27% in 2025, then jumped by 140 bps to 16.0% in 2026.
• The last three EBITDA Margin figures came in at 16.0% (Q1 2026), 40.27% (Q4 2025), and 22.36% (Q3 2025), per Business Quant data.